H.C. Andersen Bio Pharma ApS: Financial statements 2022
CVR: 38683462
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
H.C. Andersen Bio Pharma ApS (CVR 38683462) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 0 and a net result of DKK -1,357 compared with DKK -6,637 the year before. Equity in the 2022 report amounted to DKK -289,029.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -1,357
- Equity
- DKK -289,029
- Total Assets
- DKK 18,844
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 | 0 | -1 t. | -289 t. | - |
| 2021 | 0 | -5 t. | -7 t. | -288 t. | - |
| 2020 | 2 t. | -111 t. | -112 t. | -281 t. | - |
| 2019 | - | -11 t. | -12 t. | -169 t. | - |
| 2018 | 0 | -190 t. | -191 t. | -157 t. | - |
Official annual report
Keep an eye on H.C. Andersen Bio Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
H.C. Andersen Bio Pharma ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -6,637.
About H.C. Andersen Bio Pharma ApS
H.C. Andersen Bio Pharma ApS was a Danish company of the type Anpartsselskab based in København S, founded in 2017. The company has been dissolved on 24 July 2026. The company was registered under the industry Detailhandel med andre nye varer. The company was previously named H. C. Andersen Emeren Group ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,673 compared with DKK -20,418 the year before. Equity in the 2025 report amounted to DKK -312,718.